For the quarter ending 2025-12-31, VTGN has $65,056K in assets. $14,136K in debts. $47,371K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 47,371 | 62,786 | 48,985 | |
| Marketable securities | 14,399 | 14,389 | 14,195 | |
| Prepaid expenses and other current assets | 1,475 | 1,759 | 3,536 | |
| Total current assets | 63,245 | 78,934 | 66,716 | |
| Property and equipment, net | 480 | 516 | 530 | |
| Right-of-use asset - operating lease | 939 | 1,074 | 1,206 | |
| Other assets | 392 | 405 | 472 | |
| Total assets | 65,056 | 80,929 | 68,924 | |
| Accounts payable | 1,280 | 1,831 | 486 | |
| Accrued expenses | 9,254 | 8,417 | 6,582 | |
| Note payable | 379 | 658 | 933 | |
| Deferred revenue - current portion | 1,999 | 2,141 | 2,514 | |
| Operating lease obligation - current portion | 617 | 597 | 640 | |
| Total current liabilities | 13,529 | 13,644 | 11,155 | |
| Deferred revenue - non-current portion | 176 | 336 | 221 | |
| Operating lease obligation - non-current portion | 431 | 610 | 783 | |
| Total liabilities | 14,136 | 14,590 | 12,159 | |
| Common stock, 0.001 par value 325,000,000 shares authorized at december31, 2025 and march31, 2025 39,624,839 and 29,001,481 shares issued at december31, 2025 and march31, 2025, respectively | 40 | 39 | 29 | |
| Additional paid-in capital | 515,878 | 512,398 | 483,430 | |
| Treasury stock, at cost, 4,522 shares of common stock held at december31, 2025 and march31, 2025 | 3,968 | 3,968 | 3,968 | |
| Accumulated other comprehensive income | 13 | 14 | 1 | |
| Accumulated deficit | -461,043 | -442,144 | -422,727 | |
| Total stockholders equity | 50,920 | 66,339 | 56,765 | |
| Total liabilities and stockholders equity | 65,056 | 80,929 | 68,924 | |
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN)